Q1 2025 · 13F-HR
DCVC Opportunity Fund II GP, LLCholdings as filed
Filed 2025-05-15 · accession 0001104659-25-048969
$81.5M
Reported value
2
Positions
2025-03-31
Period end
The Brief · DCVC Opportunity Fund II GP, LLC · Q1 2025
AI · grounded in 13F
DCVC Opportunity Fund II GP, LLC reported no changes to its 13F holdings for 2025-03-31 relative to 2024-12-31.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 773122106 | — | Rocket Lab USA, Inc. | $60.6M | 74.3% | 3,388,249 | Common | SOLE |
| 75629V104 | RXRX | Recursion Pharmaceuticals, Inc. | $20.9M | 25.7% | 3,951,141 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.